No Data
No Data
Express News | OKYO Pharma Granted European Patent Enhancing IP Portfolio With Novel OK-101 Chemerin Analogs
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
Biodexa BDRX +52% Phase 2 Data; OKYO Pharma OKYO +26% Phase 2 Trial Plans
H.C. Wainwright Maintains OKYO Pharma(OKYO.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for OKYO Pharma on Promising Clinical Results of OK-101 for Neuropathic Corneal Pain
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
No Data